Hong Kong, 14 Jul 2026 – China Resources Pharmaceutical Group Limited (CHINARES PHARMA) announced that its 28%-owned and consolidated subsidiary, Tasly Pharmaceutical Group Co., Ltd. (Tasly Pharmaceutical), has released unaudited preliminary results for the six months ended 30 June 2026.
Tasly Pharmaceutical booked operating revenue of RMB4.20 billion, down 2.03% year on year, reflecting an industry-wide contraction in traditional Chinese medicine (TCM) injectables and lower demand for cold and fever remedies after last year’s high base.
Despite the top-line softness, operating profit rose 14.87% to RMB1.05 billion, lifting the operating margin to 25.0% from 21.3% a year earlier. Total profit advanced 15.67% to RMB1.05 billion, while net profit attributable to shareholders increased 15.23% to RMB0.89 billion. Excluding extraordinary items, attributable net profit surged 36.01% to RMB0.87 billion, underscoring a notable improvement in core profitability.
Earnings per share improved to RMB0.60 from RMB0.52, and weighted average return on equity expanded by 0.60 percentage points to 6.98%.
On the balance-sheet side, total assets were largely stable at RMB153.02 billion, edging down 0.25% from the start of the year. Equity attributable to shareholders grew 5.42% to RMB13.08 billion, driving net asset value per share up to RMB8.75.
Management attributed the profit growth to ongoing execution of Tasly’s “15th Five-Year” strategy, sharper focus on cardiovascular & metabolic, neurology & psychiatry, and gastroenterology therapies, and efficiency gains across R&D, sales, manufacturing and operations.
The disclosed figures are prepared under PRC GAAP and remain subject to audit. Final results will be detailed in Tasly Pharmaceutical’s 2026 interim report to be released on the Shenzhen Stock Exchange. Investors are advised that the information pertains solely to Tasly Pharmaceutical and does not represent the consolidated performance of CHINARES PHARMA.
Comments